US Bancorp
JNCE

US Bancorp’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

US Bancorp’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-70
Closed -$1K – 3726
2018
Q2 		$1K Buy
+70
New +$1.01K ﹤0.01% 3581
2018
Q1 		– Sell
-1,458
Closed -$18K – 3721
2017
Q4 		$18K Buy
1,458
+34
+2% +$500 ﹤0.01% 2966
2017
Q3 		$23K Hold
1,424
– – ﹤0.01% 2848
2017
Q2 		$20K Buy
+1,424
New +$30.5K ﹤0.01% 2886

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

US Bancorp's JNCE Position: Q3 2018 in Review

US Bancorp sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2018, closing a stake of 70 shares — an estimated $1K sold.

US Bancorp first reported a position in JNCE in Q2 2017 and held it in 4 quarters. The position peaked at $23K in Q3 2017. 85 funds tracked by Wall St. Rank hold JNCE as of Q3 2018.

  • US Bancorp reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • US Bancorp sold 70 Jounce Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $1K.
  • US Bancorp first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 4 quarters.
  • US Bancorp's Jounce Therapeutics, Inc. Common Stock position peaked at $23K in Q3 2017.
  • 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2018.

Based on US Bancorp's 13F filing for Q3 2018, filed 1 Nov 2018.